Atherosclerosis
Volume 196, Issue 2 , Pages 551-557 , February 2008

Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: Effects of inflammation and oxidative stress

  • Anetta Undas

      Affiliations

    • Institute of Cardiology, Jagiellonian University School of Medicine, 80 Pradnicka Str. 31-202 Cracow, Poland
    • Corresponding Author InformationCorresponding author. Tel.: +48 12 6143004; fax: +48 12 4233900.
    • ,
  • Konstanty Szułdrzynski

      Affiliations

    • Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland
    • ,
  • Ewa Stepien

      Affiliations

    • John Paul II Hospital, Cracow, Poland
    • ,
  • Jarosław Zalewski

      Affiliations

    • Institute of Cardiology, Jagiellonian University School of Medicine, 80 Pradnicka Str. 31-202 Cracow, Poland
    • ,
  • Jacek Godlewski

      Affiliations

    • John Paul II Hospital, Cracow, Poland
    • ,
  • Wiesława Tracz

      Affiliations

    • Institute of Cardiology, Jagiellonian University School of Medicine, 80 Pradnicka Str. 31-202 Cracow, Poland
    • ,
  • Mieczysław Pasowicz

      Affiliations

    • John Paul II Hospital, Cracow, Poland
    • ,
  • Krzysztof Zmudka

      Affiliations

    • Institute of Cardiology, Jagiellonian University School of Medicine, 80 Pradnicka Str. 31-202 Cracow, Poland

Received 12 April 2007 ,Revised 22 May 2007 ,Accepted 29 May 2007.

References 

  1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–3488
  2. Bini A, Fenoglio J, Mesa-Tejada E, Kudryk B, Kaplan K. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Atherosclerosis. 1989;69:1038–1045
  3. Thompson W, Smith E. Atherosclerosis and the coagulation system. J Pathol. 1989;159:97–106
  4. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci. 2001;936:11–30
  5. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architecture governed by rate and nature of fibrinogen activation. Thromb Res. 1994;5:521–538
  6. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost. 1992;68:130–135
  7. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26:2567–2573
  8. Scott EM, Ariëns RAS, Grant PJ. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:1558–1566
  9. Undas A, Zeglin M. Fibrin clot structure and cardiovascular disease. Vasc Dis Prevention. 2006;3:99–106
  10. de Maat M, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol. 2005;12:377–383
  11. Inoue N. Vascular C-reactive protein in the pathogenesis of coronary artery disease; role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets. 2006;6:227–231
  12. Beygui F, Collet J-P, Nagaswami C, Weisel JW, Montalescot G. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction. Time makes the difference. Circulation. 2006;113:e21–e23
  13. Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation. 2002;106:1938–1942
  14. Collet J-P, Mishal Z, Lesty C, et al. Abnormal fibrin clot architecture in nephritic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost. 1999;82:1482–1489
  15. von dem Borne PA, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995;86:3035–3042
  16. Lisman T, Leebeek FWG, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121:131–139
  17. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4:1029–1036
  18. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol. 1990;65:168–172
  19. Salonen EM, Vartio T, Hedman K, Vaheri A. Binding of fibronectin by the acute phase C-reactive protein. J Biol Chem. 1984;259:1496–1501
  20. Vassalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence of enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis. 2003;14:213–218
  21. Elesber AA, Best PJ, Lennon RJ. Plasma 8-iso-prostaglandin F2alpha, a marker of oxidative stress, is increased in patients with acute myocardial infarction. Free Radic Res. 2006;40:385–391
  22. Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med. 1994;17:429–437
  23. Feng YH, Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Cardiovasc Res. 1995;30:255–261
  24. Dunn E, Ariëns RAS, Grant PJ. The influence of type 2 diabetes on clot structure and function. Diabetologia. 2005;48:1198–1206

PII: S0021-9150(07)00381-4

doi: 10.1016/j.atherosclerosis.2007.05.028

Atherosclerosis
Volume 196, Issue 2 , Pages 551-557 , February 2008

Article Tools

* Image Usage & Resolution